Early Data Show Divesiran Reduces Phlebotomy Needs in Polycythemia Vera: Marina Kremyanskaya, MD, PhD

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

LONDON--(BUSINESS WIRE)--Jun 12, 2025-

Early Data Show Divesiran Reduces Phlebotomy Needs in Polycythemia Vera: Marina Kremyanskaya, MD, PhD

Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels and improving iron regulation, according to lead investigator Marina Kremyanskaya, MD, PhD.